Back to discover
Drug

Candesartan

In clinical development
ClassType-1 angiotensin II receptor antagonistEmerging researchLate-stage development

Also known as 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid, Atacand, Atacand HCT, Candesartan Cilexetil.

RxNorm214354ChEMBLCHEMBL1016ATCC09CA06UNIIS8Q36MD2XX
1
Research papers
6
Active clinical trials
Type-1 angiotensin II receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy

Clinical trial2026-07-07Results expected Q1 2028 · ClinicalTrials.gov

Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)

Clinical trial2026-06-17Results expected Q3 2031 · ClinicalTrials.gov

Early Treatment With Candesartan vs Placebo in Asymptomatic Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)"

Clinical trial2026-06-02Primary completion · ClinicalTrials.gov

A Randomised, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Oral Doses of Candesartan Cilexetil in Healthy Subjects

Clinical trial2026-01-07Results posted · ClinicalTrials.gov

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

Clinical trial2025-12-22Results expected Q3 2028 · ClinicalTrials.gov

Adiposity and Endothelin Receptor Function

Clinical trial2025-12-01Primary completion · ClinicalTrials.gov

A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA)

Clinical trial2025-01-03Results posted · ClinicalTrials.gov

Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg)

Clinical trial2024-08-08Completed · ClinicalTrials.gov

Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.

Research2023-09-25Circulation

An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Clinical trial2023-01-28Terminated · ClinicalTrials.gov

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

Clinical trial2022-12-01Results posted · ClinicalTrials.gov

A Pilot, Proof of Concept, Placebo-controlled Trial of Candesartan as an Adjunctive Treatment for Bipolar Depression

Clinical trial2022-09-01Withdrawn · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Candesartan
Aliases & brands
2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acidAtacandAtacand HCTCandesartan Cilexetil
RxNorm CUI
214354
ChEMBL ID
CHEMBL1016
ATC codes
C09CA06
UNII
S8Q36MD2XX
Primary mechanism
Type-1 angiotensin II receptor antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Type-1 angiotensin II receptor
AGTR1 · P30556
ANTAGONISTType-1 angiotensin II receptor antagonist

Clinical trials

98 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
98
registered trials across all phases
LATEST COMPLETION 2024
6
Active studies
5
Recruiting
59
Late-stage (III+)
64
Completed
28
Discontinued
PHASE DISTRIBUTIONn = 98
Early Phase 13Phase 116Phase 1 / 21Phase 219Phase 2 / 33Phase 328Phase 424Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)

Not yet recruitingPH IVStanford Universityn=1202031

SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy

Not yet recruitingPH IVOttawa Hospital Research Instituten=302028

A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

CompletedPH IVHK inno.N Corporationn=1272020

Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial.

CompletedPH IVPD Dr. Grégoire Wuerznern=782016

Renin-Angiotensin-System Quantification in Patients Treated With Aliskiren or Candesartan (RASQAL)

CompletedPH IVMedical University of Viennan=242016

Recent completions

Trials that read out recently, adding to the completed evidence base.

Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg)

CompletedPH IISt. Olavs Hospitaln=4502024

A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA)

CompletedPH IIWashington University School of Medicinen=622024

A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

CompletedPH IVHK inno.N Corporationn=1272020

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

CompletedPH IIEmory Universityn=772020

Single Dose Crossover Comparative Bioavailability Study of Candesartan Cilexetil 32 mg Tablets in Healthy Adult Subjects Under Fasting Conditions

CompletedPH IPharmtechnology LLCn=402019

CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)

CompletedPH IIEmory Universityn=1762018

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Anthracyclines1Breast Neoplasms1
Journals, researchers & institutions
Top journals
  • Circulation1
Leading researchers
  • Borley A1
  • Broom A1
  • Collins G1
  • Eddie L1
  • Everett RJ1
  • Fletcher A1
  • Guppy A1
  • Hall P1
Leading institutions
free-text, unnormalised
  • Beatson Oncology Centre1
  • BHF Centre for Cardiovascular Science (P.A.H.1
  • Edinburgh Centre1
  • Edinburgh Clinical Trials Unit1
  • Golden Jubilee National Hospital1
  • Institute of Cancer Sciences1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Carvedilol

Studied across 2 of the same disease areas as Candesartan in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials